Unity Biotechnology (LTS:0YC0) Accounts Payable: $1.76 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0YC0 Unity Biotechnology Inc LTS:0YC0
25 GF Score
Price $0.06
View Full Analysis

What is Unity Biotechnology Accounts Payable?

Unity Biotechnology LTS:0YC0 25 Accounts Payable is $1.76 Mil as of Mar. 2025. GuruFocus rates LTS:0YC0 with a GF Score™ of 25/100.

Unity Biotechnology's Accounts Payable for the quarter that ended in Mar. 2025 was $1.76 Mil.

Unity Biotechnology's quarterly Accounts Payable declined from Sep. 2024 ($1.80 Mil) to Dec. 2024 ($1.00 Mil) but then increased from Dec. 2024 ($1.00 Mil) to Mar. 2025 ($1.76 Mil).

Unity Biotechnology's annual Accounts Payable declined from Dec. 2022 ($1.79 Mil) to Dec. 2023 ($1.38 Mil) and declined from Dec. 2023 ($1.38 Mil) to Dec. 2024 ($1.00 Mil).

Unity Biotechnology Accounts Payable Related Terms

Unity Biotechnology Accounts Payable Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Accounts Payable Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 2.56 1.99 1.79 1.38 1.00

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.46 1.80 1.00 1.76
LTS:0YC0
25GF Score
Unity Biotechnology Inc LTS:0YC0
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unity Biotechnology Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.76 Mil mean?
Unity Biotechnology (LTS:0YC0) has a Accounts Payable of $1.76 Mil as of Mar. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Accounts Payable too high?
Unity Biotechnology's current Accounts Payable is $1.76 Mil. Overall, Unity Biotechnology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Unity Biotechnology's Accounts Payable compare to ADTX and HEPA?
Unity Biotechnology's Accounts Payable of $1.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Accounts Payable is $1.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (LTS:0YC0) has a current Accounts Payable of $1.76 Mil. The current Accounts Payable is $1.76 Mil. Unity Biotechnology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Unity Biotechnology (LTS:0YC0), the current Accounts Payable is $1.76 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
25GF Score

Get the complete analysis for LTS:0YC0

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price